Psilocybin

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a naturally occurring indole tryptamine alkaloid first isolated from Psilocybe mexicana by Albert Hofmann at Sandoz in 1958, synthesized the following year, and now the most extensively studied serotonergic psychedelic compound in modern clinical psychiatry. The compound is a phosphorylated prodrug that undergoes rapid first-pass dephosphorylation by alkaline phosphatase and other nonspecific phosphatases to yield psilocin (4-hydroxy-N,N-dimethyltryptamine), the pharmacologically active metabolite responsible for the full receptor pharmacology and subjective psychedelic effects. Psilocin binds the serotonin 5-HT2A receptor with moderate affinity (Ki approximately 107 to 173 nanomolar), producing agonism at the Gq/11-coupled receptor that drives the characteristic perceptual, cognitive, and emotional alterations; additional agonist activity at 5-HT2C (Ki approximately 79 to 311 nanomolar), 5-HT1A (Ki approximately 146 to 152 nanomolar), and multiple other serotonin receptor subtypes contributes to a broad serotonergic pharmacology that distinguishes psilocybin from more selective 5-HT2A agonists. Downstream of receptor activation, psilocin promotes glutamate release from cortical pyramidal neurons, activates brain-derived neurotrophic factor (BDNF) and mammalian target of rapamycin (mTOR) signaling cascades, binds the tropomyosin receptor kinase B (TrkB) receptor with affinity approximately 1000-fold greater than conventional antidepressants, and induces rapid and persistent increases in dendritic spine density in the frontal cortex, effects that collectively constitute a robust neuroplastogenic mechanism hypothesized to underlie the durable antidepressant response observed in clinical trials.

The clinical evidence base for psilocybin has expanded substantially since the landmark Griffiths et al. (2006) demonstration of sustained positive effects in healthy volunteers at Johns Hopkins University. In treatment-resistant depression, the synthetic formulation COMP360 (Compass Pathways) has achieved positive primary endpoints in two pivotal Phase 3 trials: COMP005 (single 25 mg dose versus placebo; MADRS difference of negative 3.6 points, p less than 0.001) and COMP006 (two 25 mg doses three weeks apart versus 1 mg control; MADRS difference of negative 3.8 points, p less than 0.001), with Compass Pathways advancing toward a New Drug Application submission. In cancer-related existential distress, two parallel randomized controlled trials at Johns Hopkins (Griffiths et al. 2016) and New York University (Ross et al. 2016) demonstrated clinically and statistically significant reductions in anxiety and depression sustained for six months or longer after a single high-dose session. Preliminary evidence supports efficacy in tobacco use disorder (80 percent abstinence at three months in an open-label study), alcohol use disorder (significant reduction in heavy drinking days), and obsessive-compulsive disorder (acute symptom reduction in a small open-label trial). Pharmacokinetics are characterized by rapid oral absorption (time to peak plasma psilocin approximately 2 hours), moderate bioavailability (approximately 52 percent for psilocin), extensive volume of distribution (277 to 1016 liters), metabolism primarily by CYP2D6 and CYP3A4, and a short elimination half-life (1.5 to 4 hours).

Safety data across clinical trials indicate a favorable acute tolerability profile at single or limited dosing. The principal adverse events are transient headache, nausea, anxiety, elevated blood pressure, and elevated heart rate. Psychological adverse events include challenging subjective experiences characterized by transient anxiety, paranoia, or dysphoria during the acute session, managed within structured psychotherapeutic support settings. The theoretical risk of cardiac valvulopathy through 5-HT2B receptor agonism has been raised for chronic or repeated dosing paradigms but has not been observed in clinical trial populations receiving one to three lifetime doses. Psilocybin is contraindicated in individuals with personal or family history of psychotic spectrum disorders, in concurrent lithium use (seizure risk), and requires caution with concurrent serotonergic medications. The compound is classified as Schedule I in the United States and as a controlled substance in most jurisdictions; research use requires appropriate regulatory authorization. This monograph reviews the chemistry, biosynthesis, and total synthesis of psilocybin; the prodrug activation and multi-receptor pharmacology of psilocin; the neuroplastogenic downstream mechanisms; the comprehensive human pharmacokinetic record; the preclinical and clinical evidence base across depression, anxiety, substance use disorder, and obsessive-compulsive disorder indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five psychedelic and rapid-acting antidepressant candidates against psilocybin on five competency standards.